Evidence map›Paper›PMID 37405663›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Treatment burden and health-related quality of life of patients with multimorbidity: a cross-sectional study.

Eyob Alemayehu Gebreyohannes, Begashaw Melaku Gebresillassie, Frehiwot Mulugeta, Etsegenet Dessu, Tamrat Befekadu Abebe

Abstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Analysing the impact of complex multimorbidity on health-related quality of life.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  16. Article
  17. Article
  18. Treatment Burden Among Older Adults in the United States, 2022.Journal of the American Geriatrics Society · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eyob Alemayehu Gebreyohannes *Department of Clinical Pharmacy, School of Pharmacy, University of Gondar, Gondar, Ethiopia. eyob.gebreyohannes@uwa.edu.au.ORCID http://orcid.org/0000-0002-0075-4553
Begashaw Melaku GebresillassieDepartment of Clinical Pharmacy, School of Pharmacy, University of Gondar, Gondar, Ethiopia.
Frehiwot MulugetaDepartment of Clinical Pharmacy, School of Pharmacy, University of Gondar, Gondar, Ethiopia.
Etsegenet DessuDepartment of Clinical Pharmacy, School of Pharmacy, University of Gondar, Gondar, Ethiopia.
Tamrat Befekadu Abebe *Center for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Clayton, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to investigate treatment burden and its relationship with health-related quality of life (HRQoL) among patients with multimorbidity (two or more chronic diseases) who were taking prescription medications and attending the outpatient department of the University of Gondar Comprehensive Specialized Teaching Hospital.

methodsA cross-sectional study was conducted between March 2019 and July 2019. Treatment burden was measured using the Multimorbidity Treatment Burden Questionnaire (MTBQ), while HRQoL was captured using the Euroqol-5-dimensions-5-Levels (EQ-5D-5L).

resultsA total of 423 patients participated in the study. The mean global MTBQ, EQ-5D index, and EQ-VAS scores were 39.35 (± 22.16), 0.83 (± 0.20), and 67.32 (± 18.51), respectively. Significant differences were observed in the mean EQ-5D-Index (F [2, 81.88] 33.1) and EQ-VAS (visual analogue scale) scores (F [2, 75.48] = 72.87) among the treatment burden groups. Follow up post-hoc analyses demonstrated significant mean differences in EQ-VAS scores across the treatment burden groups and in EQ-5D index between the no/low treatment burden and high treatment burden, as well as between the medium treatment burden and high treatment burden. In the multivariate linear regression model, every one SD increase in the global MTBQ score (i.e., 22.16) was associated with a decline of 0.08 in the EQ-5D index (β - 0.38, 95%CI - 0.48,  - 0.28), as well as a reduction of 9.4 in the EQ-VAS score (β - 0.51, 95%CI -0.60, - 0.42).

conclusionTreatment burden was inversely associated with HRQoL. Health care providers should be conscious in balancing treatment exposure with patients' HRQoL.

Indexed as

MultimorbidityQuality of LifeCross-Sectional StudiesHumansLinear ModelsSurveys and QuestionnairesCross-sectional studiesMultimorbidityPatient-reported outcome measuresPolypharmacyQuality of lifeTreatment burden

Identifiers

PMID37405663
PMCPMC10522511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.